Certara, a provider of decision support technology and consulting services for optimising drug development and improving health outcomes, has announced the launch of Phoenix 7.0. Phoenix is an advanced, intuitive software for pharmacokinetic (PK), pharmacodynamic (PD), and toxicokinetic (TK) modelling and simulation.
Phoenix is used by 6,000 researchers at 1,500 biopharmaceutical companies and 200 academic institutions in 60 countries. Phoenix is also employed by many global regulatory agencies for submittal review, including seven divisions of the US Food and Drug Administration (FDA).
‘PK/PD modelling and simulation has played an increasingly important role in the drug development process since its inception 30 years ago, and it is now used in more than 90 per cent of new drug and biologics approvals,’ said Certara CEO Edmundo Muniz, MD, PhD.
We are proud to be leading the industry and leveraging the largest and most advanced modelling and simulation technology and consulting portfolio. Phoenix 7.0 affirms our commitment to maintaining that preeminent position, delivering cutting-edge technology to the global drug development community.’
New features and enhancements in Phoenix 7.0 include:
- A new graphics engine which generates publication-quality images right out of the box, eliminating the need for third-party graphing tools,
- A new data layer that uses 90 per cent less memory and improves the user experience when working with large datasets or modelling projects,
- Integrated parallel computing technology, which cuts non-compartmental analysis (NCA) time by 50 per cent,
- First-in-class support for executing Phoenix NLME jobs on remote/parallel computing platforms right from the desktop application,
- The first-ever integration in a PK/PD modelling language of delay differential equations, which is a particularly important technique in complex therapeutic areas such as oncology, diabetes, and arthritis.
‘We are committed to developing the most scientifically advanced and easiest-to-use software for drug development scientists,’ said Nathan Teuscher, PhD, Certara’s vice president of pharmacometric solutions. ‘We incorporate best practices gleaned from our customers, colleagues at Certara Strategic Consulting, academic centres of excellence, and regulatory agency partners into Phoenix to make PK/PD analysis easier and more efficient. We are excited to release this powerful new set of features in Phoenix 7.0 to the global drug development community to help scientists in their efforts to develop life-saving medicines for patients.’
